Ones pre-existing c-Met Inhibitors-Adventure

References<br />1. Daley GQ, Van Etten RA, Baltimore D: Induction of persistent myelogenous<br />leukemia in mice by the P210bcr/abl gene of the Philadelphia [url=]FAK Inhibitor[/url]<br />chromosome. Science 1990, 247(4944):824–830.<br />2. Haeno H, Levine RL, Gilliland DG, Michor F: A progenitor cell origin of<br />myeloid malignancies. Proc Natl Acad Sci U S A 2009, 106(39):16616–16621.<br />3. Beissert T, Hundertmark A, Kaburova V, Travaglini L, Mian AA, Nervi C,<br />Ruthardt M: Targeting of the N-terminal coiled coil oligomerization<br />interface by a helix-two peptide inhibits unmutated and imatinib-resistant<br />BCR/ABL. Int J Most cancers 2008, 122(12):2744–2752.<br />4. Mian AA, Oancea C, Zhao Z, Ottmann OG, Ruthardt M: Oligomerization<br />inhibition, merged with allosteric inhibition, abrogates the<br />transformation likely of T315I-constructive BCR/ABL. Leukemia 2009,<br />23(12):2242–2247.<br />five. Shah NP, Sawyers CL: Mechanisms of resistance to STI571 in Philadelphia<br />chromosome-linked leukemias. Oncogene 2003, 22(47):7389–7395.<br />6. Quintas-Cardama A, Kantarjian H, Cortes J: Traveling underneath the radar: the new<br />wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007, 6(ten):834–848.